Sage Journals: Discover world-class research

Abstract

Nonadherence to inhaled therapies is a major problem in the treatment of cystic fibrosis that can influence lung function and health outcomes. Potential contributors to nonadherence have been identified, including demographic and psychosocial factors, time and convenience of inhaled therapy, and treatment beliefs. Additional research is clearly needed to clarify the contributors and to determine which interventions and technological advances will enhance adherence to inhaled therapies in patients with cystic fibrosis. Nurses and allied health professionals are ideally positioned to assist patients and families with adherence to inhaled therapies through monitoring, communication, and education about the available therapies and their proper use. This review briefly summarizes the available evidence about contributors to nonadherence, potential interventions, novel delivery devices for inhaled therapies, and opportunities for additional research.

Keywords

adherence compliance cystic fibrosis inhalation inhaled therapy

Scope of the problem

Cystic fibrosis (CF) is a chronic progressive genetic disease that affects primarily the respiratory and digestive systems. For the majority of patients, respiratory treatments can occupy hours every day [Hunter, 2003] and pancreatic enzymes must be taken with all food to aid in digestion. The treatment burden of this disease often leads to missed doses and therapies; therefore, nonadherence to CF therapy has long been recognized as a major problem [Lask, 1994]. The research of treatment adherence in CF is a high priority in nursing and allied health professions. In one survey, it received the highest ranking for all research priorities in CF [Bradley et al. 2012].

Compliance, persistence, and adherence are related, but different, terms. Compliance generally refers to the extent that a patient ‘complies’ with the prescribed treatment. Persistence refers to the extent that a patient ‘persists’ with the treatment over a given period. Adherence refers to the extent that a patient has ‘adhered’ to the prescribed therapy over a given period, and thus it usually considers both compliance and persistence. Adherence in CF varies by the specific treatment and is difficult to accurately measure. Patients are more likely to be adherent to enzyme therapy or exercise than they are to be adherent to vitamin therapy or airway clearance [Abbott et al. 1996]. Patients also tend to overestimate adherence. In a study of children with CF, parents and patients each reported approximately 90% adherence to enzyme therapy, but the actual adherence rate from electronic monitoring was only 43% [Modi et al. 2006]. In a study of adults with CF, median self-reported adherence to nebulized treatments was 80%, but data downloaded from an electronic nebulizer monitor revealed median adherence of only 36% [Daniels et al. 2011].

Patients are also more likely to be adherent to simpler therapies, such as oral medications, than they are to more burdensome time-consuming therapies, such as nebulization treatments and airway clearance techniques [Chappell and Williams, 2002; Abbott et al. 2009]. Although a majority (57%) of patients with CF who are prescribed a nebulized antibiotic use it at least once daily, only 32% are fully adherent to the prescribed treatment of two to three times a day [Latchford et al. 2009]. Clearly there is a need for additional efforts to understand and address the factors that contribute to poor adherence to inhaled therapies in patients with CF.

Adherence and outcomes

Adherence to standard CF therapies is known to improve lung function. A study dating back to 1993 demonstrated that compliance with airway clearance and routine clinic visits is associated with better forced expiratory volume in 1 second (FEV₁) trends [Patterson et al. 1993]. Other studies have correlated outcomes in patients with CF, such as reduced need for intravenous antibiotic therapy, with adherence to inhaled medications [Eakin et al. 2011]. In controlled clinical studies [Fuchs et al. 1994; Quan et al. 2001; Konstan et al. 2011b], dornase alpha treatment reduced respiratory exacerbations compared with placebo or standard care, but in an adherence study conducted by Nasr and colleagues in 2013, increase adherence to dornase alpha treatment did not reduce respiratory exacerbations significantly [Nasr et al. 2013]. This study did show that adherence to dornase alpha leads to a shorter length of hospital stay. High adherence with tobramycin inhalation solution, defined as at least four cycles per year where each cycle includes 28 days on and 28 days off therapy, is associated with a decreased risk of hospitalization and lower outpatient service costs compared with low adherence, or two or fewer cycles per year [Briesacher et al. 2011]. Thus, it is likely that patients will experience better FEV₁ outcomes with increased adherence to prescribed inhaled therapies. Identifying and addressing factors affecting adherence could lead to better health outcomes for the CF population.

Demographic and psychosocial factors

Numerous factors may contribute to medication nonadherence in pediatric patients [Modi et al. 2012], and this does not improve as the patient ages. Unfortunately, patients with CF become less adherent as they get older [Masterson et al. 2011], and by the time they are over 15 years of age they are approximately three times as likely as younger children to be noncompliant (69% versus 24%) [Arias Llorente et al. 2008]. This is often the time when care responsibilities are transitioned from parent to young adult, which may be a contributing factor to this decrease in adherence [Williams et al. 2007; Modi et al. 2008; Van Staa et al. 2011]. Gender may or may not affect adherence. Some research suggests that adolescent girls are less adherent to CF treatment than adolescent boys [Patterson et al. 2008], while other research has not found an effect of gender on adherence to CF treatment [Masterson et al. 2011].

Studies also are inconclusive about psychological associations with adherence in CF. In one study, optimistic acceptance and hopefulness were associated with greater treatment adherence in CF [Abbott et al. 2001]. Conversely, other studies conclude that patients who worry about their condition have greater adherence [Abbott et al. 1996] and children with an anxiety disorder are more likely to be adherent to CF treatment [White et al. 2009]. Data are inadequate to identify direct causality between psychological factors and adherence. However, poor psychological wellbeing can be harmful to physical wellbeing and affect disease progression [Abbott et al. 2001]. Avoidance and denial worsen treatment adherence in CF; however, the reality of the disease and its progressive nature can be a motivating factor towards adherence. A balance between psychological wellbeing and disease progression should be the target for adherence strategies [Abbott et al. 1996]. Older children and adolescents in families experiencing unhappy and conflicted relationships are at greater risk of nonadherence to CF treatment [Delambo et al. 2004; White et al. 2009].

Collectively, these findings suggest that adherence may be optimized when patients have a healthy home environment in which they can balance worry about the negative consequences of nonadherence and hopefulness about the positive outcomes of adherence. A skilled CF care team that includes nurses and allied health professionals can delicately communicate the realistic potential of disease progression without causing increased anxiety. The CF care team is instrumental in assessing patient/family understanding of the CF disease process and the need for adherence to prescribed therapies, and should assess and identify psychosocial factors that may be affecting the ability of a patient to adhere to prescribed therapy. Referral to appropriate care providers or counseling should be made available to patients and families to assist with appropriate coping skills.

Time and convenience

The total treatment regimen for CF typically requires 2–3 hours each day [Sawicki and Tiddens, 2012], and nebulized inhaled medications are a key contributor to these lengthy treatments [Hunter, 2003]. Pulmonary treatment is complex in patients with CF, particularly as they age, and the complexity of treatment has only increased over time as new life-sustaining therapies have been developed and approved [Sawicki et al. 2013]. Adolescents and children with CF report that lack of time is a leading barrier for adherence to nebulized therapy [Modi and Quittner, 2006; Dziuban et al. 2010; Bregnballe et al. 2011]. However, adolescents are significantly more adherent to nebulized therapy on school days than on weekends or holidays, when they would be expected to have more free time [Ball et al. 2013]. A possible explanation is that adolescents forget to take treatments, which is another leading reason for nonadherence in this age group [Dziuban et al. 2010; Bregnballe et al. 2011]. People are more likely to forget to perform tasks when it is not part of their daily routine. Patients should be encouraged to identify and utilize various strategies for organization, such as written schedules, behavior modification charts, or electronic reminders, to help maintain their daily treatment regimen. The importance of time and convenience is reflected by higher reported rates of adherence to oral antibiotics (80–95%) than to nebulized medications (65–80%) [Abbott et al. 1994; Conway et al. 1996; Kettler et al. 2002]. Therefore, if daily therapies were less time consuming, patients would theoretically be more likely to adhere to the prescribed regimen.

Treatment beliefs

The Health Beliefs Model, in which patient perception of disease severity is associated with treatment adherence, may not apply in patients with CF [Abbott et al. 1996]. In contrast, patient beliefs about the utility of treatment (i.e. questioning the necessity of therapy) may have a substantial effect on adherence [Kreps et al. 2011]. Adolescents are less likely to use inhaled antibiotics if they question the necessity of the treatment [Bucks et al. 2009; George et al. 2010]. Many (30%) adolescents with CF report it is acceptable to miss treatments every few days or when they are busy [Dziuban et al. 2010]. In one study, patients stated they believed respiratory therapy is important (8.0 on a scale from 0 to 10) and 62% reported they were compliant with daily respiratory medications, but 15% of patients said they only took their respiratory medications when they felt worse [Arias Llorente et al. 2008]. As CF disease progresses, adolescent patients who perceive themselves to be less healthy may be particularly nonadherent during times of decreased symptoms [Dziuban et al. 2010]. Thus, patients need to be educated about the importance of preventive and suppressive treatment of Pseudomonas aeruginosa infection in CF [Davies and Bilton, 2009] instead of treating the symptoms. Many physicians are not convinced that inhaled treatments improve lung function and reduce exacerbations [Glauser et al. 2012]. If they convey these doubts to the patient, it could worsen nonadherence to inhaled antibiotic treatment.

The challenge faced by CF care teams is to effectively change patients’ belief systems so they appropriately see the effect of their daily treatment regimen on their long-term health outcomes. If a patient does not perceive the benefit of therapy to outweigh the risk, improving the convenience is unlikely to enhance treatment adherence [Abbott et al. 2009]. At each patient visit, the potential benefits of therapy and the importance of adherence should be reinforced.

Strategies to enhance adherence in cystic fibrosis

Opportunities for interventions to improve adherence to inhaled therapy in CF are summarized in Table 1. It is important to establish a supportive, collaborative relationship with patients and families to make it clear that when they report their adherence honestly and accurately, it helps improve their care and is not a time for them to be reprimanded. Open and honest dialogue may reveal barriers to nonadherence, such as financial, psychiatric, or social stressors that may require referral to an outside agency, psychologist, or team social worker for assistance.

Table 1.

Interventions to enhance adherence to inhaled therapies in cystic fibrosis.

Factors	Intervention
Demographic and psychosocial	Communicate the realistic potential of disease progression without causing increased anxiety
	Assess patient and family understanding of the disease process and the need for adherence to prescribed therapies
	Identify psychosocial factors that may affect adherence
	Refer to appropriate care providers and/or counseling to assist with coping skills
	Routinely assess educational needs of patients and families
	Refer patients and families to educational resources such as webcasts and podcasts
Time and convenience	Encourage patients to set up electronic reminders
	Educate patients and families about technology (text reminders, mobile applications, electronic data capture in nebulizers) to support adherence
	Develop time-management strategies with a plan to reward adherence
	Encourage patients to keep a daily diary of inhaled therapy
Treatment beliefs	Reinforce the potential benefits of therapy and the importance of treatment adherence
General	Establish a supportive, collaborative relationship with patients and families
	Maintain an open and honest dialog to identify opportunities for improvement
	Consider the use of motivational interviewing, various teaching modalities, and the teach-back method
	Establish effective communication between patients, families, and healthcare professionals
	Review pharmacy refill information to assess adherence
	Consider use of a novel delivery device for inhaled therapy

Motivational interviewing should be considered [Duff and Latchford, 2010b]. It is a means to have a nonjudgmental conversation to coach patients to self identify areas they view as needing change. The patient is empowered to move from ambivalence to change with coaching. The four core counseling principles used in motivational interviewing are express empathy, support self-efficacy, roll with resistance, and develop discrepancy (www.motivationalinterviewing.org) [Levensky et al. 2007]. Conversations can bring the spirit of motivational interviewing to life by using open-ended questions, affirming the patient’s strengths, utilizing reflective listening, and recapping the discussion by summarizing important elements discussed. Healthcare professionals can begin the discussion by stating, ‘Completing all of your therapies every day is difficult. Which therapy are you most successful in accomplishing daily? With which therapy do you have the most difficulty? What would happen if you continue to miss your prescribed therapies?’ As the person with CF identifies their personal goals, motivational interviewing can lead them to realize behavior change is required to meet the goals they have set for themselves. Patients can move from nonadherence to adherence over time as they identify barriers and implement change ideas on their own.

Encouraging patients and families to keep a daily diary of inhaled therapy is often helpful and is a more accurate method than self reporting to measure adherence [Modi et al. 2006]. Patients can then bring that diary with them to the next visit to review and identify specific opportunities for improvement in adherence.

The CF care team should routinely assess the educational needs of their patients and family members. Many parents (up to 32%) of patients with CF have an incomplete understanding of their children’s treatments [Ievers et al. 1999]. Incomplete or incorrect information should be corrected using various verbal and visual teaching modalities, which could include educational brochures or links to online websites. The teach-back method [Kornburger et al. 2013] can be used to assess patient/family understanding of health-related information and instruction.

Educational programs significantly enhance patient adherence to respiratory therapy in CF [Downs et al. 2006]. Due to the infection prevention and control required for patients with CF, group educational meetings are not advisable. Instead, technology such as webcasts or podcasts is a way to safely educate a large number of patients. Patients and families can also reaccess the information if desired. The National Cystic Fibrosis Foundation has archived educational webcasts for patients and families at www.cff.org.

New technology, such as text reminders via cell phones specifically designed for patients with CF, may increase adherence in adolescents and children as young as 5 years of age [Marciel et al. 2010; Johnson et al. 2011]. Free downloadable applications are also available to remind patients with CF to take medications and track treatment adherence. Technology can also be used to monitor treatment adherence through electronic data capture in nebulizers [McNamara et al. 2009; Daniels et al. 2011; McCormack et al. 2012]. Nurses and allied health professionals can be instrumental in making patients aware of the technologies that are available and should encourage patients and parents to utilize appropriate tools.

Psychotherapeutic approaches and behavioral modification have been shown to enhance adherence to diet and airway clearance in patients with CF [Bernard and Cohen, 2004]. Behavioral modification may promote treatment adherence more effectively than education alone. In a meta-analysis of 70 psychological intervention studies to promote adherence among chronically ill youth [Kahana et al. 2008], educational interventions displayed a small effect size, whereas behavioral and multicomponent interventions had medium effect sizes. Fortunately, the average effect of interventions on treatment adherence was shown to be greater for pediatric patients with CF than for patients with other chronic pediatric conditions, such as asthma and diabetes [Kahana et al. 2008].

Establishing effective communication and interaction between patients, their families, and healthcare professionals may be a simple, yet effective, method to improve treatment adherence [Duff et al. 2010a, 2010b]. Healthcare providers often do not get an accurate representation of what patients are actually doing at home. In recent years, some pharmacies provided refill information to the prescribing care team, which may be a more accurate assessment of what medications patients are not taking as prescribed, but the potential for inaccuracy remains. Evaluation of refill information can be used as a starting point for assessing adherence barriers and spur discussion between healthcare professionals and their patients and families.

The general strategies described here to improve adherence are a good starting point, but it is important to identify the specific barriers to adherence in an individual patient with CF and then target the interventions to that patient’s needs [Abbott et al. 2009]. Information to identify barriers may be collected via personal interview or by survey. Nurses or other team members can then partner with the patient and families to develop time-management strategies with a plan to reward adherence. Strategies to improve adherence also need to be age appropriate and properly balanced between targeting the patient and their caregiver.

Novel delivery devices for inhaled therapies

Clinical guidelines recommend inhaled tobramycin therapy in patients aged 6 years or older with persistent P. aeruginosa infection [Flume et al. 2007]. Inhalation solutions approved for the management of P. aeruginosa in patients with CF in the USA include tobramycin and aztreonam lysine [Ballmann et al. 2011]. Until recently, clinical guidelines concluded that other inhaled antibiotics have less evidence than tobramycin inhalation solution to support their use in this setting [Flume et al. 2007; Ryan et al. 2011]. A recent study of inhaled aztreonam lysine by nebulizer three times daily reported that it improved lung function and reduced pulmonary exacerbations more effectively than tobramycin inhalation solution by nebulizer twice daily [Assael et al. 2013]. The 2013 update to CF pulmonary guidelines from the CF Foundation supported the use of either inhaled tobramycin or inhaled aztreonam lysine [Mogayzel et al. 2013].

Nebulizers for inhalation solutions can be time consuming, not only to administer the drug, but also to clean and prepare the nebulizer [Heijerman et al. 2009]. Technologies such as vibrating-mesh nebulizers, jet nebulizers, and ultrasonic nebulizers may shorten administration time [Heijerman et al. 2009; Coates et al. 2011; Daniels et al. 2013; Govoni et al. 2013], but not all nebulizers are approved for the administration of all inhaled medications. A nebulizer may have a faster delivery time, but the medication will not be delivered properly and thus does not have its optimal affect. Administration of inhaled antibiotics in a dry powder inhaler reduces the time required for administration as compared with nebulizers and is more convenient and portable [Geller and Madge, 2011; Parkins and Elborn, 2011]. A dry powder inhaler for tobramycin that was approved for use in patients with CF with P. aeruginosa infection is more effective than placebo and is not inferior to tobramycin inhaled solution [Geller et al. 2007; Konstan et al. 2011a; Galeva et al. 2013]. Although more rapid administration with a dry powder inhaler has been postulated to improve treatment adherence, this has not been studied directly. Additional research and development of other novel administration devices [Kesser and Geller, 2009; Hofmann, 2012], other antibiotics in dry powder inhalers [Schuster et al. 2013], and combinations of inhaled medications [Trapnell et al. 2012; Pilcer et al. 2013a, 2013b] are ongoing in an effort to enhance delivery of inhaled therapies and improve adherence.

In the course of ongoing communication with patients and families, if the nebulized administration of antibiotic therapy is determined to be likely to interfere with treatment adherence, use of a novel delivery device should be considered.

Conclusion

Despite widespread recognition that nonadherence is a major problem in CF treatment and emerging research about potential contributors to nonadherence, additional research is clearly needed to determine which interventions and technological advances will enhance adherence to inhaled therapies in patients with CF. In the meantime, nurses and allied health professionals are ideally positioned to assist patients with CF and their families with adherence to inhaled therapies, through monitoring, communication, and education about the available therapies and their proper use.

Footnotes

Acknowledgements

The author thanks Jonathan Latham of PharmaScribe, LLC for editorial assistance and styling of the manuscript for journal submission.

Funding

Novartis Pharmaceuticals Corporation (East Hanover, NJ) provided funding for the editorial assistance. The opinions expressed in this manuscript are those of the author. Novartis Pharmaceuticals Corporation had no influence on the contents of the manuscript.

Conflict of interest statement

The author declares that there is no conflict of interest.

References

Abbott

Dodd

Bilton

Webb

(1994) Treatment compliance in adults with cystic fibrosis. Thorax 49: 115–120.

Abbott

Dodd

Gee

Webb

(2001) Ways of coping with cystic fibrosis: implications for treatment adherence. Disability & Rehabilitation 23: 315–324.

Abbott

Dodd

Webb

(1996) Health perceptions and treatment adherence in adults with cystic fibrosis. Thorax 51: 1233–1238.

Abbott

Havermans

Hart

(2009) Adherence to the medical regimen: clinical implications of new findings. Curr Opin Pulm Med 15: 597–603.

Arias Llorente

Bousono Garcia

Diaz Martin

. (2008) Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros 7: 359–367.

Assael

Pressler

Bilton

Fayon

Fischer

Chiron

. (2013 2012) Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 12: 130–140.

Ball

Southern

McCormack

Duff

Brownlee

McNamara

(2013) Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week-days during school term-time. J Cyst Fibros 12: 440–444.

Ballmann

Smyth

Geller

(2011) Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Respir Med 105(Suppl. 2): S2–S8.

Bernard

Cohen

(2004) Increasing adherence to cystic fibrosis treatment: a systematic review of behavioral techniques. Pediatr Pulmonol 37: 8–16.

10.

Bradley

Madge

Morton

Quittner

Elborn

(2012) Cystic fibrosis research in allied health and nursing professions. J Cyst Fibros 11: 387–392.

11.

Bregnballe

Schiotz

Lomborg

(2011) Parenting adolescents with cystic fibrosis: the adolescents’ and young adults’ perspectives. Patient Prefer Adherence 5: 563–570.

12.

Briesacher

Quittner

Saiman

Sacco

Fouayzi

Quittell

(2011) Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med 11: 5.

13.

Bucks

Hawkins

Skinner

Horn

Seddon

Horne

(2009) Adherence to treatment in adolescents with cystic fibrosis: the role of illness perceptions and treatment beliefs. J Pediatr Psychol 34: 893–902.

14.

Chappell

Williams

(2002) Rates and reasons for non-adherence to home physiotherapy in paediatrics: pilot study. Physiotherapy 88: 138–147.

15.

Coates

Denk

Leung

Ribeiro

Chan

Green

. (2011) Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatr Pulmonol 46: 401–408.

16.

Conway

Pond

Hamnett

Watson

(1996) Compliance with treatment in adult patients with cystic fibrosis. Thorax 51: 29–33.

17.

Daniels

Goodacre

Sutton

Pollard

Conway

Peckham

(2011) Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 140: 425–432.

18.

Daniels

Mills

Whitaker

(2013) Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst Rev 4: CD007639.

19.

Davies

Bilton

(2009) Bugs, biofilms, and resistance in cystic fibrosis. Respir Care 54: 628–640.

20.

Delambo

Ievers-Landis

Drotar

Quittner

(2004) Association of observed family relationship quality and problem-solving skills with treatment adherence in older children and adolescents with cystic fibrosis. J Pediatr Psychol 29: 343–353.

21.

Downs

Roberts

Blackmore

Le Souef

Jenkins

(2006) Benefits of an education programme on the self-management of aerosol and airway clearance treatments for children with cystic fibrosis. Chron Respir Dis 3: 19–27.

22.

Duff

Latchford

(2010a) Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: poor adherence and the need to address it. J Cyst Fibros 9: 455–456.

23.

Duff

Latchford

(2010b) Motivational interviewing for adherence problems in cystic fibrosis. Pediatr Pulmonol 45: 211–220.

24.

Dziuban

Saab-Abazeed

Chaudhry

Streetman

Nasr

(2010) Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis. Pediatr Pulmonol 45: 450–458.

25.

Eakin

Bilderback

Boyle

Mogayzel

Riekert

(2011) Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 10: 258–264.

26.

Flume

O’Sullivan

Robinson

Goss

Mogayzel

Jr Willey-Courand

. (2007) Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Resp Crit Care Med 176: 957–969.

27.

Fuchs

Borowitz

Christiansen

Morris

Nash

Ramsey

. (1994) Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 331: 637–642.

28.

Galeva

Konstan

Higgins

Angyalosi

Brockhaus

Piggott

. (2013) Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized edit trial. Curr Med Res Opin 29: 947–956.

29.

Geller

Konstan

Smith

Noonberg

Conrad

(2007) Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 42: 307–313.

30.

Geller

Madge

(2011) Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis. Respir Med 105(Suppl. 2): S24–S31.

31.

George

Rand-Giovannetti

Eakin

Borrelli

Zettler

Riekert

(2010) Perceptions of barriers and facilitators: self-management decisions by older adolescents and adults with CF. J Cyst Fibros 9: 425–432.

32.

Glauser

Nevins

Williamson

Abdolrasulnia

Salinas

Zhang

. (2012) Adherence to the 2007 cystic fibrosis pulmonary guidelines: a national survey of CF care centers. Pediatr Pulmonol 47: 434–440.

33.

Govoni

Poli

Acerbi

Santoro

Cicirello

Annoni

. (2013) Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. Pulmon Pharmacol Ther 26: 249–255.

34.

Heijerman

Westerman

Conway

Touw

Doring

(2009) Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 8: 295–315.

35.

Hofmann

(2012) New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa. Curr Pharm Des 18: 683–695.

36.

Hunter

(2003) The daily grind and how to stay sane as a mother of two children with cystic fibrosis. J R Soc Med 96(Suppl. 43): 51–56.

37.

Ievers

Brown

Drotar

Caplan

Pishevar

Lambert

(1999) Knowledge of physician prescriptions and adherence to treatment among children with cystic fibrosis and their mothers. J Dev Behav Pediatr 20: 335–343.

38.

Johnson

Culpepper

Scott

Gordon

Harris

(2011) The utility of providing automated medication dose reminders to young children on chronic medication. J Telemed Telecare 17: 387–391.

39.

Kahana

Drotar

Frazier

(2008) Meta-analysis of psychological interventions to promote adherence to treatment in pediatric chronic health conditions. J Pediatr Psychol 33: 590–611.

40.

Kesser

Geller

(2009) New aerosol delivery devices for cystic fibrosis. Respir Care 54: 754–767; discussion 767-758.

41.

Kettler

Sawyer

Winefield

Greville

(2002) Determinants of adherence in adults with cystic fibrosis. Thorax 57: 459–464.

42.

Konstan

Flume

Kappler

Chiron

Higgins

Brockhaus

. (2011a) Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the Eager Trial. J Cyst Fibros 10: 54–61.

43.

Konstan

Wagener

Pasta

Millar

Jacobs

Yegin

. (2011b) Clinical use of dornase alpha is associated with a slower rate of Fev1 decline in cystic fibrosis. Pediatr Pulmonol 46: 545–553.

44.

Kornburger

Gibson

Sadowski

Maletta

Klingbeil

(2013) Using ‘teach-back’ to promote a safe transition from hospital to home: an evidence-based approach to improving the discharge process. J Pediatr Nurs 28: 282–291.

45.

Kreps

Villagran

Zhao

Mchorney

Ledford

Weathers

. (2011) Development and validation of motivational messages to improve prescription medication adherence for patients with chronic health problems. Patient Educ Couns 83: 375–381.

46.

Lask

(1994) Non-adherence to treatment in cystic fibrosis. J R Soc Med 87(Suppl. 21): 25–27.

47.

Latchford

Duff

Quinn

Conway

Conner

(2009) Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns 75: 141–144.

48.

Levensky

Forcehimes

O’Donohue

Beitz

(2007) Motivational interviewing: an evidence-based approach to counseling helps patients follow treatment recommendations. Am J Nurs 107: 50–58; quiz 58–59.

49.

Marciel

Saiman

Quittell

Dawkins

Quittner

(2010) Cell phone intervention to improve adherence: cystic fibrosis care team, patient, and parent perspectives. Pediatr Pulmonol 45: 157–164.

50.

Masterson

Wildman

Newberry

Omlor

(2011) Impact of age and gender on adherence to infection control guidelines and medical regimens in cystic fibrosis. Pediatr Pulmonol 46: 295–301.

51.

McCormack

Southern

McNamara

(2012) New nebulizer technology to monitor adherence and nebulizer performance in cystic fibrosis. J Aerosol Med Pulm Drug Deliv 25: 307–309.

52.

McNamara

McCormack

McDonald

Heaf

Southern

(2009) Open adherence monitoring using routine data download from an adaptive aerosol delivery nebuliser in children with cystic fibrosis. J Cyst Fibros 8: 258–263.

53.

Modi

Lim

Geller

Wagner

Quittner

(2006) A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 5: 177–185.

54.

Modi

Marciel

Slater

Drotar

Quittner

(2008) The influence of parental supervision on medical adherence in adolescents with cystic fibrosis: developmental shifts from pre to late adolescence. Children’s Health Care 37: 78–92.

55.

Modi

Pai

Hommel

Hood

Cortina

Hilliard

. (2012) Pediatric self-management: a framework for research, practice, and policy. Pediatrics 129: e473–e485.

56.

Modi

Quittner

(2006) Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way? J Pediatr Psychol 31: 846–858.

57.

Mogayzel

Jr Naureckas

Robinson

Mueller

Hadjiliadis

Hoag

. (2013) Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Resp Crit Care Med 187: 680–689.

58.

Nasr

Chou

Villa

Chang

Broder

(2013) Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. J Med Econ 16: 801–808.

59.

Parkins

Elborn

(2011) Tobramycin inhalation powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 5: 609–622.

60.

Patterson

Budd

Goetz

Warwick

(1993) Family correlates of a 10-year pulmonary health trend in cystic fibrosis. Pediatrics 91: 383–389.

61.

Patterson

Wall

Berge

Milla

(2008) Gender differences in treatment adherence among youth with cystic fibrosis: development of a new questionnaire. J Cyst Fibros 7: 154–164.

62.

Pilcer

De Bueger

Traina

Traore

Sebti

Vanderbist

. (2013a) Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. Int J Pharm 451: 112–120.

63.

Pilcer

Rosiere

Traina

Sebti

Vanderbist

Amighi

(2013b) New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J Pharm Sci 102: 1836–1846.

64.

Quan

Tiddens

McKenzie

Montgomery

Robinson

. (2001) A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 139: 813–820.

65.

Ryan

Singh

Dwan

(2011) Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev CD001021.

66.

Sawicki

Ren

Konstan

Millar

Pasta

Quittner

(2013) Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros 12: 461–467.

67.

Sawicki

Tiddens

(2012) Managing treatment complexity in cystic Fibrosis: challenges and opportunities. Pediatr Pulmonol 47: 523–533.

68.

Schuster

Haliburn

Doring

Goldman

(2013) Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 68: 344–350.

69.

Trapnell

McColley

Kissner

Rolfe

Rosen

McKevitt

. (2012) Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Resp Crit Care Med 185: 171–178.

70.

Van Staa

Jedeloo

Van Meeteren

Latour

. (2011) Crossing the transition chasm: experiences and recommendations for improving transitional care of young adults, parents and providers. Child: Care, Health & Development 37: 821–832.

71.

White

Miller

Smith

McMahon

(2009) Adherence and psychopathology in children and adolescents with cystic fibrosis. Eur Child Adolesc Psychiatry 18: 96–104.

72.

Williams

Mukhopadhyay

Dowell

Coyle

(2007) From child to adult: an exploration of shifting family roles and responsibilities in managing physiotherapy for cystic fibrosis. Soc Sci Med 65: 2135–2146.

Enhancing adherence to inhaled therapies in cystic fibrosis

Abstract

Keywords

Scope of the problem

Adherence and outcomes

Demographic and psychosocial factors

Time and convenience

Treatment beliefs

Strategies to enhance adherence in cystic fibrosis

Novel delivery devices for inhaled therapies

Conclusion

Footnotes

Acknowledgements

Funding

Conflict of interest statement

References